Plasminogen improves lung lesions and hypoxemia in patients with COVID-19

Y. Wu1,*, T. Wang1,*, C. Guo1, D. Zhang2, X. Ge1, Z. Huang1, X. Zhou3, Y. Li4, Q. Peng4 and J. Li

From the 1Department of Basic Research, Talengen Institute of Life Sciences, Shenzhen, P.R. China, 2Department of Respiratory Medicine, Beijing Chang’an Chinese and Western Integrated Medicine Hospital, Beijing, P.R. China, 3Department of Respiratory Medicine, Suixian Hongshan Hospital, Suizhou, Hubei Province, P.R. China and 4Department of Respiratory Medicine, Xiaogan Hospital, Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei Province, P.R. China

Address correspondence to J. Li PhD, Department of Basic Research, Talengen Institute of Life Sciences, Room C602G, 289 Digital Peninsula, Shunfeng Industrial Park, No.2 Red Willow Road, Futian District, Shenzhen, P.R. China. email: jnl@talengen-pharma.com

*These authors contributed equally to this work.

Summary

Background: Lungs from patients with coronavirus disease 2019 (COVID-19) have shown typical signs of acute respiratory distress syndrome (ARDS), formation of hyaline membrane mainly composed of fibrin and 'ground-glass' opacity. Previously, we showed plasminogen itself is a key regulator in fibrin degradation, wound healing and infection.

Aim: We aimed to investigate whether plasminogen can improve lung lesions and hypoxemia of COVID-19.

Design: Thirteen clinically moderate, severe or critical COVID-19 patients were treated with atomization inhalation of freeze-dried plasminogen.

Methods: Levels of their lung lesions, oxygen saturation and heart rates were compared before and after treatment by computed tomography scanning images and patient monitor.

Results: After plasminogen inhalation, conditions of lung lesions in five clinically moderate patients have quickly improved, shown as the decreased range and density of 'ground glass' opacity. Improvements of oxygen saturation were observed in six clinically severe patients. In the two patients with critical conditions, the oxygen levels have significantly increased from 79–82% to 91% just about 1 h after the first inhalation. In 8 of 13 patients, the heart rates had slowed down. For the five clinically moderate patients, the difference is even statistically significant. Furthermore, a general relief of chest tightness was observed.

Conclusion: Whereas it is reported that plasminogen is dramatically increased in adults with ARDS, this study suggests that additional plasminogen may be effective and efficient in treating lung lesions and hypoxemia during COVID-19 infections. Although further studies are needed, this study highlights a possible hope of efficiently combating this rapid epidemic emergency.

Received: 24 March 2020; Revised (in revised form): 1 April 2020

© The Author(s) 2020. Published by Oxford University Press on behalf of the Association of Physicians.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

Since December 2019, a sudden outbreak of infectious pneumonia (coronavirus disease 2019 [COVID-19]) caused by novel coronavirus, SARS-CoV-2, occurred in Wuhan, Hubei Province, China and is quickly spreading national wide and also to other parts of the world.1 As of 4 March 2020, the virus has been found in 59 countries with 80,710 confirmed cases in China, including 3,045 fatalities.2 Due to rapid transmission dynamics and multiple transmission ways, COVID-19 has caused panic in the world.

The clinical features of COVID-19 are very similar to that of severe acute respiratory syndrome-like coronavirus (SARS) outbreak in 2003.3,4 In the early phases of the disease, acute respiratory infection symptoms occur. Although in most cases the disease is acute and can be resolved by itself, in severe or critical cases, patients may suffer and even die from acute respiratory distress syndrome (ARDS), acute respiratory failure and other serious complications, mainly due to massive diffuse alveolar damage and early hyaline membrane formation.5,6

As a predominant and early pathological feature, formed hyaline membranes consist of fibrin matrix incorporating the whole spectrum of serum proteins and cellular debris,6–8 which forms a barrier to inhibit gas exchange and pulmonary surfactant resulting in ARDS. Moreover, in hyaline membrane disease of premature infants, fibrin deposition in alveoli and alveolar ducts is a crucial factor that may result in death.9,10

The plasminogen activator (PA) system is a broad-spectrum protease system where the active component, plasmin, is formed from its precursor, plasminogen and is important in degrading main components of the extracellular matrix including fibrin. Plasminogen is classically regarded as inert and excessive, and the regulation of the PA system is by the activators and inhibitors of the system.11 However, we have shown before that plasminogen itself is a key regulator in many pathological processes including fibrinolysis, wound healing and infection.12–15

Previous studies have demonstrated different results on whether plasminogen is sufficient in ARDS. Premature infants with hyaline membrane disease and ARDS have been reported to have low levels of circulating plasminogen and PA system,9,16–18 but increased levels of the PA inhibitor.16 Thus, intravenous supplementation of plasminogen was effective in lowering the occurrence of premature infant ARDS and death.9,17,18 However, other studies later on showed that in the bronchoalveolar lavage of the normal adult patients with ARDS, dramatically increased and sufficient amounts of plasminogen, reduced levels of urokinase-type PA and markedly enhanced levels of PA inhibitor-1 and s2-antiplasmin were found.19,20

Hence, although hyaline membrane disease in premature infants and COVID-19 pneumonia mainly in normal adults have completely distinct aetiologies, inspired by our previous studies, we hypothesize that additional plasminogen supplementation to these COVID-19 patients may still benefit them. As the first attempt, in this study, we investigated the therapeutic effects of plasminogen by atomization inhalation on COVID-19. The attempt, in this study, we investigated the therapeutic effects of plasminogen by atomization inhalation on COVID-19. The aim of the study was to determine whether plasminogen is sufficient in ARDS. Premature infants and COVID-19 pneumonia mainly in normal adults have completely distinct aetiologies, inspired by our previous studies, we hypothesize that additional plasminogen supplementation to these COVID-19 patients may still benefit them. As the first attempt, in this study, we investigated the therapeutic effects of plasminogen by atomization inhalation on COVID-19.

Materials and methods

Patient involvement

The 13 study subjects were 30–78 years old females and males diagnosed as COVID-19 with clinically moderate, severe or critical clinical severities, in accordance with the National Health Commission guidelines.21 The clinical study was performed during 10th to 20th of February 2020, as a joint research between Talengen Institute of Life Sciences and Beijing Chang’an Chinese and Western Integrated Medicine Hospital and executed at Xiaogan Hospital and Suxian Hongshan Hospital. Ethics Committee of Beijing Chang’an Chinese and Western Integrated Medicine Hospital approved the study and the study was performed according to the Declaration of Helsinki. Subjects gave their informed consent before included in the study. Written informed consent was waived by the Ethics Committee for emerging infectious diseases.

Administration of plasminogen

Sterile, freeze-dried plasminogen of 5 mg per vial from human plasma fraction III was produced at facilities with GMP compliance and provided by Talengen Institute of Life Sciences. The safety of the virus inactivation process was confirmed by an independent third party testing organization. Atomization inhalation of 10 mg plasminogen dissolved in 2-ml sterile water was given twice daily for severe and critical COVID-19 subjects, and once daily for moderate COVID-19 subjects. Treatment profile is shown in Table 1.

Computed tomography scan

High-resolution computed tomography (CT) scan (NeuViz 16 Classic, Neusoft, China) of the chest was taken at Suxian Hongshan Hospital a few days before the first and after the last administration of plasminogen for the five moderate COVID-19 subjects.

Oxygen saturation and heart rate examination

Real-time oxygen saturation and heart rates were monitored by patient monitor (iPM5, Mindary, China) of the chest was taken at Suxian Hongshan Hospital a few days before the first and after the last administration of plasminogen for the five moderate COVID-19 subjects.

Table 1. Treatment profiles of plasminogen for COVID-19 patients

| Patient ID | Gender | Age (years old) | Severity of disease | Inhalation times of plasminogen |
|------------|--------|-----------------|---------------------|-------------------------------|
| 1          | Male   | 58              | Moderate            | 2                             |
| 2          | Male   | 30              | Moderate            | 2                             |
| 3          | Female | 49              | Moderate            | 2                             |
| 4          | Female | 48              | Moderate            | 3                             |
| 5          | Male   | 48              | Moderate            | 2                             |
| 6          | Male   | 46              | Severe              | 6                             |
| 7          | Male   | 78              | Severe              | 6                             |
| 8          | Male   | 47              | Severe              | 2                             |
| 9          | Male   | 65              | Severe              | 2                             |
| 10         | Female | 56              | Severe              | 4                             |
| 11         | Male   | 78              | Severe              | 1                             |
| 12         | Male   | 48              | Critical            | 5                             |
| 13         | Male   | 47              | Critical            | 2                             |

Statistical analysis

Statistical analysis was performed on SPSS 16.0 (IBM Corporation). Heart rate of the same severity group before and after administration of plasminogen was analyzed with
Results

Plasminogen improves lung lesions of clinically moderate COVID-19 patients

To study the effects of plasminogen on lung lesions, high-resolution CT scanning of chest was performed on COVID-19 patients. Before administration of plasminogen, the chest CT images of five moderate COVID-19 patients showed multiple patchy/punctate ‘ground-glass’ opacities in bilateral lungs with unclear margins and heterogeneous density, and also scattered punctate density in mediastinum (Figure 1 and Table 2). Despite the five patients received the daily common supportive treatments with antibiotics and traditional Chinese medicine, the density and range of ‘ground glass’ opacities in lung increased over time, suggesting a rapid deleterious progress of the disease (CT scanning examination record, not shown here). Surprisingly, just after two to three times of plasminogen inhalation, the CT results showed that the numbers, the range and
plasminogen rapidly improves lung lesions caused by COVID-19 infection.

**Plasminogen improves oxygen saturation of clinically severe and critical COVID-19 patients**

We further investigated the effects of plasminogen on oxygen saturation. Throughout the entire plasminogen administration period, the oxygen saturation levels were detected by patient monitors on clinically severe or critical COVID-19 patients with oxygen supplementation by a nasal cannula that delivered oxygen at constant concentrations of at least 80% or 100%, respectively. As shown in Table 3, although generally having good oxygen saturation levels, the oxygen saturation values of five out of six severe COVID-19 patients still increased 1–4% after plasminogen administration. Only in one patient, perhaps due to administration of plasminogen for just once, the oxygen saturation value decreased from 91% to 89%. In these two patients, they were transferred to intensive care unit, so that the follow-up treatment of plasminogen was interrupted. Nevertheless, these data indicate that plasminogen generally improves the oxygen saturation levels of severe and critically severe COVID-19 patients, especially in these patients that have particularly low oxygen levels.

**Plasminogen improves heart rates of COVID-19 patients**

All of the COVID-19 patients also underwent heart rate examination during the study. The results showed that whereas before inhalation of plasminogen, these patients generally showed higher heart rates. After treatment, in 8 out of 13 COVID-19 patients, the heart rates had slowed down as much as 26 beats per min, 2 increased and 3 no changes. Statistical analysis showed that despite patient samples are sparse, the average heart rates after treatment in general have decreased in all of the three groups and for the moderate group, the statistics reached significance ($P < 0.05$) (in Table 4 and Figure 2). These results indicate that plasminogen can generally slow down the
wound healing. Previous studies showed that adults with diabetes and hypertension have significantly enhanced levels of plasminogen in their blood at a steady concentration about 0.2 mg/ml.23 Traditionally, as an inactive pre-enzyme, it is well known and almost a doctrine that plasminogen is excessive, inert and does not have any functional roles due to plasminogen circulating in the blood at a steady concentration about 0.2 mg/ml.23 However, we have shown that although plasminogen levels are significantly increased in the wounded area of diabetic mice, systemic supplementation of plasminogen results in an even further local increase and faster wound healing, suggesting that plasminogen itself has active functional roles during wound healing.12 Previous studies showed that adults with ARDS have dramatically increased and sufficient amounts of plasminogen, reduced levels of urokinase-type PA and markedly enhanced levels of PA inhibitor-1 and α2-antiplasmin.19–20 Therefore, it is reasonable, similar to that during diabetic wound healing, we speculated that addition of plasminogen can also improve the lung lesions in COVID-19 patients, at least by promoting the degradation of alveolar fibrin.

Meanwhile, our CT results precisely demonstrated that administration with plasminogen indeed decreases the ‘ground glass’ opacity and lesion focal in bilateral lungs of moderate COVID-19 patients. Bilateral lung involvement with ‘ground glass’ opacity is the most common finding from CT images of the COVID-19 patient chests.24 ‘Ground glass’ opacity shown on CT image of viral pneumonia typically represents the filling of the alveolar spaces with macrophages, fibrin, hyaline membranes, proliferating and reactive pneumocytes and hemorrhage.25 Interestingly, it is known that the PA system regulates many of the above components found in the filling of the alveolar space. Thus, these findings suggest that supplementation of plasminogen, such as through atomization inhalation, can be an effective way to remove the ‘ground glass’ opacity, and therefore to restore respiratory function during viral pneumonia in general.

Inflammatory exudation and hyaline membranes form a barrier to gas exchange and inhibit pulmonary surfactant, which is essential for proper pulmonary expansion.26,27 leading to acute respiratory distress and tissue hypoxia. The oxygen saturation results in our study demonstrated that plasminogen does improve hypoxemia of severe and critically severe COVID-19 patients. Of interest, in 1970s, two double-blind randomized clinical studies have indicated that plasminogen improves the clinical conditions and decreases the death rate caused by the hyaline membrane disease, although the studies were performed on premature newborns that were reported to have low circulating plasminogen.9,17 In our study, all of the patients self-described the relief of chest tightness and smoother breathing soon after each administration of plasminogen.

Several studies on hospitalized patients have shown that hypertension, diabetes, cardiovascular diseases are the common comorbidities and lung, kidney, liver and heart are the organs easily affected by the COVID-19 infection.28,29 Earlier studies by us have shown that plasminogen can be used in treating these diseases and diseased organs.30–35 Thus, together with the regulation mechanism of the PA system, we predict that, intravenous supplementation of plasminogen, with or without inhalation of plasminogen, should have more comprehensive and effective therapeutic effects, although additional cautions need to note, due to the complicated nature of COVID-19 infection.

As it is the first and a quick study with limited resources, therefore, a major drawback of the study is the lack of a proper control untreated group. However, since the conditions of these COVID-19 patients are quickly worsening as described in the results section, and by our clinicians’ judgments, it would be difficult for these patients to recover by themselves or by conventional treatment methods during the treatment period. Thus, one could generally regard the conditions before plasminogen treatment are these patients’ own controls, so-called single arm study. Above all, the key findings of rapid clinical improvements by just plasminogen inhalation are stunning. This means that plasminogen inhalation is an efficient and effective method to relieve the COVID-19 patients from the hyaline membrane formation and ARDS. As ARDS is the key event that can quickly worsen the COVID-19 lung conditions from flu-like discomfort to multi-organ failures and even death. We speculate that, if this treatment method can be used more extensively at a larger scale, especially to patients with clinical conditions quickly turning from moderate to severe or critical, we might significantly lower the death rate and the severity of this terrible epidemic emergency. Notwithstanding, before the above conclusions can be firmly made, randomized controlled trials and additional examination parameters and methods are needed to determine the efficacy and optimize the safety profile...
of plasminogen for treatment of patients with SARS-CoV-2 infection, such work is currently being carried on by our team.

Acknowledgements
We wish to acknowledge all other staff involved in the study from but not limited to the institutions of the listed authors for their assistance.

Conflict of interest. J.L. owns Talengen Institute of Life Sciences. The institute has applied patents on the use of plasminogen in relation to COVID-19 and is developing natural and recombinant plasminogen as a drug candidate to treat COVID-19. Other authors have declared no competing interests.

References
1. World Health Organization. Pneumonia of Unknown Cause-China. 2020. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/ (19 February 2020, date last accessed).
2. Real-Time Big Data Report on New Coronavirus Pneumonia. 2020. https://voice.baidu.com/act/newpneumonia/newpneumonia/? from=osari_pc_3 (4 March 2020, date last accessed).
3. Hui DSC, Wong PC, Wang C. SARS: clinical features and diagnosis. Respirology 2003; 8: S20–4.
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–13.
5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8: 420–22.
6. Gitlin D, Craig JM. The nature of the hyaline membrane in asphyxia of the newborn. Pediatrics 1956; 17:64–71.
7. Van Breemen VL, Neustein HB, Bruns PD. Pulmonary hyaline membranes studied with the electron microscope. Am J Pathol 1956; 33:769–89.
8. Duran-Jorda F, Holzel A, Patterson WH. A histochemical study of pulmonary hyaline membrane. Arch Dis Child 1956; 31:113–8.
9. Ambrus CM, Weintraub DH, Choi TS, Eisenberg B, Henry PS, Norman GC, et al. Plasminogen in the prevention of hyaline membrane disease. Res Commun Chem Pathol Pharmacol 1973; 6:341–4.
10. Günther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001; 2: 353–64.
11. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988; 4:93–126.
12. Shen Y, Guo Y, Mikus P, Sulniute R, Wilczynska M, Ny T, et al. Plasminogin is a key proinflammatory regulator that accelerates the healing of acute and diabetic wounds. Blood 2012; 119:5879–87.
13. Guo Y, Li J, Hagström E, Tor NY. Beneficial and detrimental effects of plasminogen during infection and sepsis in mice. PLoS One 2011; 6:e24774.
14. Guo Y, Li J, Hagström E, Tor NY. Protective effects of plasminogen in Staphylococcus aureus-induced arthritis. Arthritis Rheum 2008; 58:764–72.
15. Li J. Method for preventing or treating acute thrombosis and chronic thrombosis. WIPO Patent Application, WO/2017/101866.
16. Lieberman J, Kellogg F. The fibrinolytic enzyme defect of hyaline membrane disease. Calif Med 1961; 95:278–82.
17. Ambrus CM, Choi TS, Cunnanan E, Eisenberg B, Staub HP, Weintraub DH, et al. Prevention of hyaline membrane disease with plasminogen: a cooperative study. JAMA 1977; 237: 1837–41.
18. Ambrus CM, Choi TS, Weintraub DH, Eisenberg B, Staub HP, Courey NG, et al. Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogen. Semin Thromb Hemost 2002; 2:42–51.
19. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Mauder RJ, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84:695–705.
20. Günther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart F, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161:454–62.
21. General Office of National Health Commission of the People’s Republic of China. Office of State Administration of Traditional Chinese Medicine. Notice on the issuance of strategic guidelines for diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (fifth edition draft) (2020-02-05) [EB/OL].
22. Real-Time Big Data Report on Global New Coronavirus Pneumonia. 2020. https://news.qq.com/zt2020/page/feiyan.htm?kw=ad_sy#/global (4 March 2020, date last accessed).
23. Aisina RB, Mukhametova LI. Structure and function of plasminogen/plasmin system. Russ J Biochem 2014; 40: 590–605.
24. Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol 2020.
25. El-Sherief AH, Gilman MD, Healey TT, Tambouret RH, Shepard JA, Abbott GF, et al. Clear vision through the haze: a practical approach to ground-glass opacity. Curr Probl Diagn Radiol 2014; 43:140–58.
26. Avery ME. The Lung and Its Disorders in Newborn Infants. Pediatrics September 1969; 44: 465–466.
27. Taylor FB Jr, Abrams ME. Effect of surface active lipoprotein on clotting and fibrinolysis, and of fibrinogen on surface tension of surface active lipoprotein. Am J Med 1966; 40:346–50.
28. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323:1061.
29. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–62.
30. Li J. Method for preventing and treating tissue and organ fibrosis. WIPO Patent Application, WO/2018/107698.
31. Li J. Method for mitigating heart disease. WIPO Patent Application, WO/2018/107707.
32. Li J. Novel method for preventing and treating cardiovascular disease. WIPO Patent Application, WO/2017/101871.
33. Li J. Method for preventing and treating pulmonary fibrosis. WIPO Patent Application, WO/2018/107697.
34. Li J. Novel method for treating diabetes. WIPO Patent Application, WO/2018/107702.
35. Li J. Method and drug for regulating blood pressure. Chinese Patent Application, CN/202010119730.9